Key facts
- This page summarizes GordonMD Global Investments LP's Form 3 filing for Pyxis Oncology, Inc. (PYXS).
- 0 reported transactions and 4 derivative rows are listed below.
- Accepted by SEC: 10 Jul 2026, 16:10.
GordonMD Global Investments LP - 30 Jun 2026 Form 3 Insider Report for Pyxis Oncology, Inc. (PYXS)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- PYXS
- Reported as of
- 30 Jun 2026
- Net transaction value
- $0
- Reporting owner signature
- GordonMD Global Investments LP, By: GordonMD Global Investments GP LLC, /s/ Craig D. Gordon, Managing Member
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
GordonMD Global Investments LP filed Form 3 for Pyxis Oncology, Inc. (PYXS) on 10 Jul 2026.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (4)
CIK 0002039349
Primary reporting owner
GordonMD Global Investments LP
- Relationship
- 10%+ Owner
- Address
- 9460 WILSHIRE BLVD, SUITE 420, BEVERELY HILLS
- Signature
- GordonMD Global Investments LP, By: GordonMD Global Investments GP LLC, /s/ Craig D. Gordon, Managing Member
- Signature date
- 10 Jul 2026
CIK 0002103789
GordonMD Long Biased Master Fund LP
- Relationship
- 10%+ Owner
- Address
- 9460 WILSHIRE BLVD, SUITE 420, BEVERLY HILLS
- Signature
- GordonMD Long Biased Master Fund LP, By: GordonMD Long Biased GP LLC, /s/ Craig D. Gordon, Managing Member
- Signature date
- 10 Jul 2026
CIK 0002103778
GordonMD Long Biased GP LLC
- Relationship
- 10%+ Owner
- Address
- 9460 WILSHIRE BLVD, SUITE 420, BEVERLY HILLS
- Signature
- GordonMD Long Biased GP LLC, /s/ Craig D. Gordon, Managing Member
- Signature date
- 10 Jul 2026
CIK 0002103811
Gordon Craig D
- Relationship
- 10%+ Owner
- Address
- 9460 WILSHIRE BLVD, SUITE 420, BEVERLY HILLS
- Signature
- Craig D. Gordon, /s/ Craig D. Gordon
- Signature date
- 10 Jul 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PYXS
holding
Common Stock, par value $0.001 per share
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 10,024,909
- Date
- 30 Jun 2026
- Ownership
- See footnote
- Footnotes
- F1
PYXS
holding
Common Stock, par value $0.001 per share
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 10,024,909
- Date
- 30 Jun 2026
- Ownership
- See footnote
- Footnotes
- F1
PYXS
holding
Common Stock, par value $0.001 per share
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 10,024,909
- Date
- 30 Jun 2026
- Ownership
- See footnote
- Footnotes
- F1
PYXS
holding
Common Stock, par value $0.001 per share
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 10,024,909
- Date
- 30 Jun 2026
- Ownership
- See footnote
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
PYXS
holding
Derivative
Common Stock Purchase Warrant
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 30 Jun 2026
- Ownership
- Direct
- Underlying class
- Common Stock, par value $0.001 per share
- Underlying amount
- 4,900,039
- Exercise price
- $3.29
- Footnotes
- F2, F3
PYXS
holding
Derivative
Common Stock Purchase Warrant
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 30 Jun 2026
- Ownership
- Direct
- Underlying class
- Common Stock, par value $0.001 per share
- Underlying amount
- 4,900,039
- Exercise price
- $3.29
- Footnotes
- F2, F3
PYXS
holding
Derivative
Common Stock Purchase Warrant
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 30 Jun 2026
- Ownership
- Direct
- Underlying class
- Common Stock, par value $0.001 per share
- Underlying amount
- 4,900,039
- Exercise price
- $3.29
- Footnotes
- F2, F3
PYXS
holding
Derivative
Common Stock Purchase Warrant
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 30 Jun 2026
- Ownership
- Direct
- Underlying class
- Common Stock, par value $0.001 per share
- Underlying amount
- 4,900,039
- Exercise price
- $3.29
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The securities to which this filing relates are held directly by GordonMD Long Biased Master Fund LP (the "Master Fund") to which GordonMD Global Investments LP (the "Investment Manager") serves as investment manager. Craig D. Gordon ("Mr. Gordon") is the managing member of GordonMD Long Biased GP LLC (the "GP"), the general partner of the Master Fund. Each of the Master Fund, the GP and Mr. Gordon disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any.
Footnote F2
The Common Stock Purchase Warrant is exercisable on or after the earlier of (i) the date on which the Issuer first publicly discloses clinical data from its micvotabart pelidotin (MICVO) Phase 1 monotherapy study in 2L+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) and (ii) October 1, 2026.
Footnote F3
Exercise price of $3.289, subject to adjustments as set forth in the Common Stock Purchase Warrant.